Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (December 2023)
31 slides from Cocrystal Pharma's investor presentation, Dec 4, 2023
Slide 1: Slide 1
Slide 2: Forward-Looking Statements
-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; our
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets +» Pandemic and seasonal influenza A * Pandemic SARS-CoV-2, SARS-CoV-2 variants, and coronaviruses Applying powerful, proprietary * Norovirus gastroenteritis drug discovery platform Drug candidates with clinically validat
Slide 4: Investment Highlights
Investment Highlights e Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases » Proprietary structure-based drug-discovery platform technology provides opportunity for discovery and development of novel, potent, broad-spectrum drug candidates » Advancin
Slide 5: Program
Program CC-42344 oral Influenza A PB2 Inhibitor Influenza A/B Inhibitor CC-42344 Inhaled PB2 inhibitor Influenza A/B Influenza A Phase 1 Phase 2 Phase 3 Phase 2a trial initiated in collaboreRWiED €> MERCK > Planned Phase 1 trial CDI-988 Oral CoOvID-19 Protease Inhibitor COVID-19 CDI-45205 Protease (
Slide 6: Proprietary Discovery Platform Technology for Direct-Acting Antivirals
Proprieta Discovery Platform Technology for Direct-Acting Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select Drug Hit-to-lead Lead . . we x-ray crystals binding pocket process optimization Direct-
Slide 7: Pandemic and Seasonal Influenza A Program
Pandemic and Seasonal Influenza A Program
Slide 8: Pandemic and Seasonal Influenza: A Major Global Health Concern
Pandemic and Seasonal Influenza: A Major Global Health Concern * 1 billion cases, 3-5 million severe illnesses and up to 650,000 deaths worldwide annually" * Not well managed with currently approved vaccines having only 40-60% effectiveness? * On average ~8% of the U.S. population contracts influenz
Slide 9: Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication
Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication Trimeric RNA Polymerase Complex Nucleus ‘ 4 WY vil nna cia mRNA (2 chimeric RNA rn “Cap snatching” Pe Bi endonrye™ Boivin Set al. J. Biol. Chem. 2010;285:28411-28417 cytoplasm elF4E Translation \
Slide 10: CC-42344: Pandemic and Seasonal Influenza A Therapeutic and Prophylactic
CC-42344: Pandemic and Seasonal Influenza A Therapeutic and Prophylactic * Potent anti-influenza structure-based inhibitor Pandemic and seasonal influenza A PB2 crystals - - - (HIN1, H2N2, H3N2, HSN1, and H7N9) * Binds a highly conserved region of influenza A PB2 of polymerase complex (PA:PB1:PB2) C
Slide 11: Oral CC-42344: Phase 1 Data Demonstrates Favorable Safety Profile
Oral CC-42344: Phase 1 Data Demonstrates Favorable Safety Profile Phase 1 site: Linear Clinical Research — Harry Perkins Research Institute, Perth, Australia Participants: = Single-center, randomized, double-blind, placebo-controlled = Single-ascending dose, multiple-ascending dose; 7-day nontreatme
Slide 12: CC-42344 Oral PB2 Inhibitor: Phase 1 Trial Summary & Phase 2a Trial Design
CC-42344 Oral PB2 Inhibitor: Phase 1 Trial Summary & Phase 2a Trial Design * Phase 1 study healthy volunteer trial completed * No serious or grade 3 AEs reported * No treatment discontinuations * No clinically significant observations noted in laboratory assessments, vital signs, physical exam findi
Slide 13: Advantages of inhalation antiviral therapy
13 Advantages of inhalation antiviral therapy * Directly targets infected respiratory epithelial cells * Achieves higher accumulation of drug in the pulmonary system * Produces rapid clinical response * Reduces potential systemic side effects C@CRYSTAL
Slide 14: Influenza-Infected Lung Epithelium
i | Influenza-Infected Lung Epi Uninfected human bronchial airway epithelia Influenza A @ H1N1 infection ay Gellsere-killed by HIN virus,and_ most cilia are destroyed= ~ “No CC-42344 Favorable safety profile: No toxicity in CC-42344- treated human lung epithelium Showed potent antiviral activity in
Slide 15: CC-42344: Potential Influenza Therapeutic and Prophylactic Treatment
CC-42344: Potential Influenza Therapeutic and Prophylactic Treatmen ° Favorable safety profile ° Potent, broad-spectrum activity against pandemic and seasonal strains ° High barrier to resistance * Superior pulmonary pharmacology: high exposure and long half-life, EC50 >5,000- fold at 96 hours after
Slide 16: Influenza A/B Program with Merck
Influenza A/B Program with € MERCK
Slide 17: Collaboration Validates Technology with Potential for Milestones and Royalties
Collaboration Validates Technology with Potential for * Broad-spectrum, potent candidates developed to be active against seasonal, pandemic and existing drug-resistant influenza A and B strains * Announced exclusive worldwide license and collaboration with Merck in January 2019 Cocrystal eligible to
Slide 18: SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
Slide 19: Significant Need for New Antivirals to Combat Coronavirus Infections
Significant Need for New Antivirals to Combat Coronavirus Infections ° Pfizer's paxlovid (nimatrevir plus ritonavir) received FDA approval as oral treatment for COVID-19 in adults » Merck's molnupiravir received emergency use authorization; Shionogi’s Ensitrelvir received emergency regulatory approv
Slide 20: Oral Main (3CL) Protease and Replication Inhibitors
Oral Main (3CL) Protease and Replication Inhibitors SARS -CoV-2 Infected cell Structural RNA Polyproteins RNA aes —= (8) —@) = @) —@) Translation Proteolysis Replication Translation Main (3CL) protease inhibitor 20 Membrane a fusion Assembly Endocytosis AiG Uncoating C@CRYSTAL PHAR
Slide 21: SARS-CoV-2
SARS-CoV-2 . 2 ‘SARS-CoV-1_POC6UB MERS_RON638 cea pace? 2208 poceo2 ‘res-Poceos 24
Slide 22: CDI-988: Pandemic COVID-19 Oral Main (3CL) Protease Inhibitor
CDI-988: Pandemic COVID-19 Oral Main (3CL) Protease Inhibitor SARS-CoV-2 main protease (1.8A) SARS-CoV-1main protease (1.56 A) MERS-CoV main protease (1.9 A) CDI-988 oral inhibitor 4 « Binds to a highly conserved, essential residue (Cys145) of SARS-CoV-2 main (3CL) protease and other coronavirus mai
Slide 23: CDI-988 Phase 1 Trial Underway & Phase 2 COVID-19 Trial Design
CDI-988 Phase 1 Trial Underway & Phase 2 COVID-19 Trial Design « Phase 1 trial with orally administered CDI-988 e Randomized, placebo-controlled, double-blind, single-ascending dose/multiple-ascending dose trial » Conducted in healthy volunteers in Australia « Evaluate safety, tolerability, PK and e
Slide 24: Norovirus Gastroenteritis Program
Norovirus Gastroenteritis Program
Slide 25: Norovirus: Large Market with No Approved Treatments or Vaccines
ovirus: Large Market with No Approved Treatments or Vaccines * Highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea * Major cause of gastrointestinal illness in closed and crowded environments including hospitals, nursing homes,
Slide 26: Selection of Broad-Spectrum Protease Inhibitor CDI-988 as Norovirus Lead
Selection of Broad-Spectrum Protease Inhibitor CDI-988 as Norovirus Lead * Dual indication oral protease inhibitor, CDI-988, for the treatment of coronavirus and norovirus infections * CDI-988 discovered using proprietary drug discovery platform * Phase 1 healthy volunteer trial underway * Targets h
Slide 27: Seasoned Leadership
Seasoned Leadership Sam Lee, Ph.D. + Professor Co-Chief Executive Officer & Roger Kornberg, Ph.D. , President Chairman of the Board, Chairman of the _Stanford University School of Medicine ao a Scientific Advisory Board + Nobel Laureate 25+ years of anti-infective drug icos ” discovery research expe
Slide 28: Experienced Board of Directors
Experienced Board of Directors Roger Kornberg, Ph.D. Co-founder, Chairman of the Board & Chairman of the Scientific Advisory Board + Nobel Laureate in Chemistry + Welch Prize ~ highest award granted in the field of chemistry in the U.S. + Leopald Mayer Prize ~ highest award granted in the field of b
Slide 29: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus * Issued patents in U.S. and major countries * Issued patents in U.S. and major countries * Pending U.S. provisional applications * Pending U.S. provisional applications Pandemic Influenza A HCV * PB2 (influenza A inhibitor) NSS5B (NNI)
Slide 30: Financial Snapshot
Financial Snapshot ~$20 Million 27,000 Market cap? Average 3 month daily share volume" 10.3 Million Fully diluted shares Clean balance sheet No preferred shares No debt Cash sufficient to fund planned operations * Yahoo Finance (November 27, 2023) 30 CSCI TAL
Slide 31: Investment Highlights
Investment Highlights e Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases » Proprietary structure-based drug-discovery platform technology provides opportunity for discovery and development of novel, potent, broad-spectrum drug candidates » Advancin
Cocrystal Pharma — Investor Presentation (December 2023) on 6ix